Navigation Links
PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results

BOSTON, Oct. 24 /PRNewswire-FirstCall/ --

First Quarter Highlights:

- Consolidated revenue of $208.1 million grows 26% year-over-year

- Diluted EPS up 40% to $0.35 year-over-year, excluding a favorable

benefit of $0.14 related to one-time non-U.S. net tax adjustments

PAREXEL International Corporation (Nasdaq: PRXL) today announced its financial results for the first quarter ended September 30, 2007.

For the three months ended September 30, 2007, PAREXEL's consolidated service revenue increased 26.1% to $208.1 million compared with $165.1 million in the prior year period. The Company reported operating income of $16.5 million, or 7.9% of service revenue, versus operating income of $11.3 million, or 6.9% of service revenue, in the comparable quarter of the prior year. Net income for the quarter totaled $13.9 million, or $0.49 per diluted share, compared with net income of approximately $7.0 million, or $0.25 per diluted share, for the quarter ended September 30, 2006, representing earnings per share growth of 96%. Excluding one-time non-U.S. net tax adjustments of $4.0 million or $0.14 per diluted share, related in part to a recent change in German tax rates, net income and earnings per diluted share would have been $9.9 million (up 42%) and $0.35 (up 40%), respectively.

On a segment basis, consolidated service revenue for the first quarter of Fiscal Year 2008 was $159.3 million in Clinical Research Services (CRS), $30.5 million in PAREXEL Consulting and Medical Communications Services (PCMS), and $18.3 million in Perceptive Informatics, Inc.

The Company has made certain reclassifications to the financial results for Fiscal Year 2007 to conform to Fiscal Year 2008 presentation. The reclassifications were made to ensure consistency across business segments and to better clarify the geographic breakout of revenue earned. A spreadsheet which details these changes may be found in the "Additional Financials" portion of the Investor Relations section of the Company's website at

PAREXEL's backlog increased 31.3% year-over-year, and 4.2% sequentially, to $1.570 billion at the end of the September quarter. As of June 30, 2007, PAREXEL's backlog totaled $1.507 billion. Adding the September quarter's gross new business wins of $349.5 million to that amount, and subtracting $208.1 million in current quarter service revenue and $78.0 million in cancellations, left the Company with a backlog of $1.570 billion as of September 30, 2007. The net book-to-burn ratio in the quarter was 1.31.

Mr. Josef H. von Rickenbach, PAREXEL's Chairman and Chief Executive Officer stated, "During the September quarter we continued to execute well, with year-over-year revenue growth of 26%, a 100 basis point improvement in operating margin, and normalized EPS growth of 40%. During the quarter we completed the acquisition of APEX International, which represents a major strategic accomplishment for the Company. The integration process is well underway, and we are confident that APEX will enable us to achieve our objectives, better serve clients, and solidify our global footprint in the rapidly growing Asia Pacific market."

Mr. von Rickenbach continued, "We believe that the market demand for our services remains solid. Going forward, we will continue to drive revenue growth, execute well on our projects, and further increase profitability so that we can deliver another successful year to our clients and shareholders."

The Company issued forward-looking guidance for the second quarter of Fiscal Year 2008 (ending December 31, 2007), and for Fiscal Year 2008. For the second quarter, the Company anticipates reporting consolidated service revenue in the range of $220 to $230 million and earnings per diluted share in the range of $0.37 to $0.39. For Fiscal Year 2008, consolidated service revenue is expected to be in the range of $890 to $920 million using recent exchange rates (previously issued revenue guidance was $875 to $910 million). Earnings per diluted share for Fiscal Year 2008 are projected to be in the range of $1.75 and $1.81, including the one-time net tax benefit of $0.14 which was recognized in the first quarter (versus previously issued guidance for earnings per diluted share of $1.58 to $1.66).

The Company believes that presenting the proforma information contained in the financial tables and in this press release assists investors and others in gaining a better understanding of its core operating results and future prospects, especially when comparing such results to previous periods or forecasted guidance. Management uses this proforma information, in addition to the GAAP information, as the basis for measuring the Company's core operating performance and comparing such performance to that of prior periods and to the performance of its competitors. Such measures are also used by management in its financial and operating decision-making. Proforma information is not meant to be considered superior to or a substitute for the Company's results of operations prepared in accordance with GAAP. A reconciliation of GAAP results with proforma results may be found in the attached financial tables.

A conference call to discuss PAREXEL's first quarter earnings, business, and financial outlook will begin at 10 a.m. ET Thursday, October 25th and will be broadcast live over the internet via webcast. The webcast may be accessed in the "Webcasts" portion of the Investor Relations section of the Company's website at Users should follow the instructions provided to ensure that the necessary audio applications are downloaded and installed. A replay of this webcast will be archived on the website approximately two hours after the call and will continue to be accessible for approximately one year following the live event. To participate via telephone, dial 612-332-0228 and ask to join the PAREXEL quarterly conference call.

About the Company

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 64 locations throughout 51 countries around the world, and has over 7,050 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand, such as the guidance provided by the Company with respect to the second quarter of Fiscal Year 2008, and Fiscal Year 2008. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward- looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears", "estimates", "projects", "targets" and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward- looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the period ended June 30, 2007 as filed with the SEC on August 27, 2007, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.


James Winschel, Senior Vice-President and Chief Financial Officer

Jill Baker, Vice President of Investor Relations

(781) 434-4118

PAREXEL International Corporation

Consolidated Condensed Statement of Operations

(In thousands, except per share data)


For the three months ended September 30,

2007 2006

Service revenue $208,125 $165,057

Reimbursement revenue 43,907 38,450

Total revenue 252,032 203,507

Costs and expenses:

Direct costs 136,062 108,488 (b)

Reimbursable out-of-pocket

expenses 43,907 38,450

Selling, general and

administrative 47,140 38,772 (b)

Depreciation 7,496 6,143

Amortization 899 407

Restructuring benefit - (74)

Income from operations 16,528 11,321

Other income (expense) (426) 483

Income before income taxes 16,102 11,804

Provision for income taxes 2,237 (a) 4,816

Effective tax rate 13.9% (a) 40.8%

Minority interest expense (benefit) (20) 11

Net income $13,885 $6,977

Earnings per common share:

Basic $0.50 $0.26

Diluted $0.49 $0.25

Shares used in computing earnings

per common share:

Basic 27,621 27,052

Diluted 28,541 27,930

Balance Sheet Information Preliminary

Sept 30, June 30, Sept 30,

2007 2007 2006

Billed accounts receivable, net $205,002 $189,843 $173,100

Unbilled accounts receivable, net 149,378 135,178 122,554

Deferred revenue (173,972) (170,718) (156,573)

Net receivables $180,408 $154,303 $139,081

Cash and marketable securities $50,436 $96,677 $84,217

Working capital $75,958 $118,746 $140,570

Total assets $735,660 $680,013 $554,947

Short-term borrowings $55,463 $30,463 $5,494

Stockholders' equity $343,087 $316,616 $260,237

(a) Includes a one-time non-U.S. net tax benefit of $4 million, related

in part to a recent reduction in German tax rates.

(b) FY 2007 numbers have been adjusted to reflect FY 2008 presentation.

Certain Direct costs have been moved to Selling, general and

administrative to ensure consistency among all business segments.

PAREXEL International Corporation

Segment Information

($ in thousands)

Three months ended

September 30,

2007 2006 *

Clinical Research Services (CRS)

Service revenue $159,329 $120,236

% of total service revenue 76.5% 72.8%

Gross profit $55,162 $41,299

Gross margin % of service revenue 34.6% 34.3%

PAREXEL Consulting & Medical Communications

Services (PCMS)

Service revenue $30,520 $29,310

% of total service revenue 14.7% 17.8%

Gross profit $9,581 $9,153

Gross margin % of service revenue 31.4% 31.2%

Perceptive Informatics, Inc. (PII)

Service revenue $18,276 $15,511

% of total service revenue 8.8% 9.4%

Gross profit $7,320 $6,117

Gross margin % of service revenue 40.1% 39.4%

Total service revenue $208,125 $165,057

Total gross profit $72,063 $56,569

Gross margin % of service revenue 34.6% 34.3%

Revenue by Geography

The Americas $79,999 $64,646

Europe, Middle East & Africa 112,843 92,600

Asia/Pacific 15,283 7,811

Total service revenue $208,125 $165,057

Quarterly Supplemental Financial Data

Total revenue $252,032 $203,507

Investigator fees 39,093 29,816

Gross revenue $291,125 $233,323

DSO 57 55

Capital expenditures 13,036 8,578

* FY 2007 numbers have been adjusted to reflect FY 2008 presentation.

Certain Direct costs have been moved to Selling, general and

administrative to ensure consistency among all business segments.

SOURCE PAREXEL International Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
(Date:11/25/2015)... Md. , Nov. 25, 2015  PharmAthene, Inc. ... Directors has adopted a stockholder rights plan (Rights Plan) ... net operating loss carryforwards (NOLs) under Section 382 of ... --> PharmAthene,s use of its NOLs ... "ownership change" as defined in Section 382 of the ...
(Date:11/25/2015)... Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and CEO of Neurocrine Biosciences, will be presenting ... New York . ... website approximately 5 minutes prior to the presentation to ... the presentation will be available on the website approximately ...
(Date:11/25/2015)... The Global Genomics Industry ... and in-depth study on the current state of ... ) , The report provides ... classifications, applications and industry chain structure. The Genomics ... including development trends, competitive landscape analysis, and key ...
(Date:11/24/2015)... Cepheid (NASDAQ: CPHD ) today announced ... conference, and invited investors to participate via webcast. ... December 1, 2015 at 11.00 a.m. Eastern Time ... December 1, 2015 at 11.00 a.m. Eastern Time ... York, NY      Tuesday, December 1, 2015 at ...
Breaking Biology Technology:
(Date:11/30/2015)... , Nov. 30, 2015  BIOCLAIM announced ... finalist in this year,s Fierce Innovation Awards:  Healthcare Edition, ... FierceHealthIT , FierceHealthcare , ... as a finalist in the category of "Privacy ... --> --> ...
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Sensors - Technology and Patent Infringement Risk Analysis" ... --> Fingerprint sensors using capacitive technology ... fingerprint sensor vendor Idex forecasts an increase of 360% ... devices and of the fingerprint sensor market between 2014 ...
(Date:11/20/2015)... Connecticut , November 20, 2015 ... authentication company focused on the growing mobile commerce market ... CEO, Gino Pereira , was recently interviewed on ... interview will air on this weekend on Bloomberg ... Latin America . --> NXTD ) ("NXT-ID" ...
Breaking Biology News(10 mins):